Evidence map›Paper›PMID 35565413›Full record

ReviewCancers2022

In Vitro Human Cancer Models for Biomedical Applications.

Jane Ru Choi, Gül Kozalak, Ighli di Bari, Quratulain Babar, Zahra Niknam, Yousef Rasmi, Kar Wey Yong

Abstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Autophagy-related mechanisms for treatment of multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jane Ru ChoiLife Sciences Centre, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.ORCID 0000-0002-1537-6989
Gül KozalakFaculty of Engineering and Natural Sciences (FENS), Sabanci University, Istanbul 34956, Turkey.ORCID 0000-0002-2928-6474
Ighli di BariDialysis and Transplantation Unit, Department of Emergency and Organ Transplantation-Nephrology, University of Bari, 70124 Bari, Italy.
Quratulain BabarDepartment of Biochemistry, Government College University, Faisalabad 38000, Pakistan.ORCID 0000-0002-0078-9676
Zahra NiknamProteomics Research Center, Shahid Behesti University of Medical Sciences, Tehran 1983969411, Iran.
Yousef RasmiDepartment of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia 5714783734, Iran.ORCID 0000-0003-1506-1909
Kar Wey YongFaculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R7, Canada.ORCID 0000-0002-9761-9402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the leading causes of death worldwide, and its incidence is steadily increasing. Although years of research have been conducted on cancer treatment, clinical treatment options for cancers are still limited. Animal cancer models have been widely used for studies of cancer therapeutics, but these models have been associated with many concerns, including inaccuracy in the representation of human cancers, high cost and ethical issues. Therefore, in vitro human cancer models are being developed quickly to fulfill the increasing demand for more relevant models in order to get a better knowledge of human cancers and to find novel treatments. This review summarizes the development of in vitro human cancer models for biomedical applications. We first review the latest development in the field by detailing various types of in vitro human cancer models, including transwell-based models, tumor spheroids, microfluidic tumor-microvascular systems and scaffold-based models. The advantages and limitations of each model, as well as their biomedical applications, are summarized, including therapeutic development, assessment of tumor cell migration, metastasis and invasion and discovery of key cancer markers. Finally, the existing challenges and future perspectives are briefly discussed.

Indexed as

biomedical applicationscancer markershuman cancersin vitro modeltherapeutic developmenttumor biology

Identifiers

PMID35565413
PMCPMC9099454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.